RecruitingNon Small Cell Lung Cancer

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

Sponsor: University of Louisville

✓ suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
✓ treatment naive or no treatment within 6 months prior to enrollment
✓ able to swallow pills
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
✓ absolute neutrophil count (ANC) at least 1500/microl
✓ able to understand and willing to sign a written informed consent document
✓ resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon
✓ treatment naive

✕ history of hypersensitivity reactions attributed to beta-glucan
✕ currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
✕ presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
✕ AIM 3:
✕ history of hypersensitivity reactions attributed to beta-glucan
✕ currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
✕ presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Louisville

Source: ClinicalTrials.gov · NCT00682032 · last updated 2025-01-10